Greg D. Judy, MD, of UNC Health Care, discusses the contributing factors, and possible fixes, for near-miss and actual safety incidents in patients being treated with radiotherapy.
John V. Cox, DO, MBA, of the Parkland Health System/UTSW, discusses some of the key presentations at the 2017 Quality Care Symposium (Abstracts 3, 37, 52).
Robert S. Miller, MD, of ASCO, updates the progress of CancerLinQ and its data set, now being used by oncologists to track quality measurement and reporting.
Thomas J. Smith, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes two papers for which he was a discussant: reducing overuse of colony-stimulating factors without compromising the safety of patients with lung cancer receiving chemotherapy, and a cost-and-survival analysis before and after implementing Dana-Farber Clinical Pathways for patients with stage IV non–small cell lung cancer (Abstracts 3, 52).
Brian Weiss, MD, of Cincinnati Children’s Hospital Medical Center, discusses a program designed to eliminate errors in chemotherapy use among pediatric patients whose regimens incorporate multiple drugs and rigorous monitoring schedules (Abstract 37).
Nicole Mittmann, PhD, of the Sunnybrook Health Sciences Centre, discusses her study findings on transitioning breast cancer survivors to primary care and the savings in resources and dollars that accrued as a result (Abstract 1).
